Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Intellia Therapeutics Q3 2026 Results: Net Loss of $127M, Loss Widens

Intellia Therapeutics reported a net loss of $127.5 million for the third quarter of 2026, driven by a decrease in collaboration revenue and increased general and administrative expenses. The company strengthened its balance sheet during the nine months ended September 30, 2026, through a follow-on public offering and new debt issuance, resulting in total cash, cash equivalents, and marketable securities of approximately $614.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue7.213.8
Net income-127.5-101.3
EPS (diluted, $ a share)$-0.91$-0.92

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-48.0%
Source

10-Q filed with the SEC, NASDAQ: NTLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Intellia Therapeutics, Inc.: key numbers

Share price
$9.86Close, Nov 16
Market cap
$1.38B
Shares outstanding
140.36MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Intellia Therapeutics, Inc.

All →
5:06 PM ET 8-K/A
Investor Presentation

Intellia Therapeutics Investor Presentation

Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.

4:15 PM ET 8-K
Investor Presentation

Intellia Therapeutics Investor Presentation

Intellia Therapeutics hosted a webcast for investors and analysts titled 'Readying Lonvo-z for Patients with HAE' to discuss the development and commercialization strategy for its CRISPR-based therapy, lonvoguran ziclumeran. The presentation focused on the clinical data and market potential for lonvo-z in treating hereditary angioedema (HAE).

8:16 AM ET 8-K
Financial Results

Intellia Therapeutics Financial Results

Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.

Counterparty
Regeneron Pharmaceuticals, Inc.
Term
Q3 2026

“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”

John Leonard, M.D., Intellia President and Chief Executive Officer
4:21 PM ET Form 4
Insider Selling

Intellia Therapeutics President and CEO John M. Leonard Sells $108K of Stock

John M. Leonard, President and CEO, sold 9,000 shares of Intellia Therapeutics, Inc. at $11.99 a share, worth $108K in total on Nov 2, 2026. Shares held after the trade: 1,138,064 (-0.8%).

Value
$108K
Shares
9,000
Price
$11.99
Role
President and CEO
Holding change
-0.8%
Trade date
Nov 2, 2026
4:05 PM ET Form 4
Insider Selling

Intellia Therapeutics VP, CAO Michael P. Dube Sells $23.2K of Stock

Michael P. Dube, VP, CAO, sold 1,864 shares of Intellia Therapeutics, Inc. at $12.43 a share, worth $23.2K in total on Oct 2, 2026. Shares held after the trade: 65,022 (-2.8%).

Value
$23.2K
Shares
1,864
Price
$12.43
Role
VP, CAO
Holding change
-2.8%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.